TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04529135
Drug: Remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The prepared drug marks the assigned group as unknown. In both groups, the test drug marked as unknown begins to be administered in an anesthetic induction. When the patient arrives in the operating room, electrocardiogram, noninvasive blood pressure, and bispectral index (BIS) monitoring is performed. In both groups, 2 mg/kg of propofol induces general anesthesia, intubates after administration of rocuronium 0.6 mg/kg, and maintains anesthesia with sevoflurane 1.5-2.5 vol%. Use 0.075 mg of palonosetrone as an antiemetics after inducing anesthesia. Adjust the inhalation anesthetic to maintain BIS 40-60 , mechanical ventilation to maintain the Tidal volume of 8 ml/kg, PEEP 5 mmHg and end-tidal carbon dioxide (EtCO2) of 35-40 mmHg. Push 1mcg of fentanyl and 1g of acetaminophen per kg for pain control 20 minutes before the end of surgery.
Study: NCT02172807
Drug: Placebo MDI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo metered dose inhaler (MDI)
Study: NCT02172807
Drug: Placebo inhalation capsule
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02168881
Drug: Dinoprostone
Normalized name: Dinoprostone
DrugBank: Dinoprostone (DB00917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01263093
Drug: LY2216684
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01915108
Drug: Remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All patients received a predetermined Ce of remifentanil by TCI according to their group assignments 10 minutes before the end of surgery (R0, remifentanil Ce of 0 ng/ml; R0.5, remifentanil Ce of 0.5 ng/ml; R1.0, remifentanil Ce of 1.0 ng/ml; R1.5, remifentanil Ce of 1.5 ng/ml).
Study: NCT02236741
Drug: Mirapexin® (Sifrol®)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00120289
Drug: Simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dose adjusted to achieve LDL-C 40 mg/dL - 80 mg/dL, adding ezetimibe (10 mg/day) if needed to achieve LDL-C target
Study: NCT02858973
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00614653
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 400 mg/m\^2 PO Twice Daily on days with radiation.
Study: NCT03213977
Drug: R-DA-EPOCH
Normalized name: pantolactone, (R)-
Approvals — FDA: no, EMA: no, PMDA: no
Description: R-DA-EPOCH-21 treatment for DLBCL patients between 16 to 60 years with high risk. Patients who meet the criteria for ASCT after reaching CR or PR will undergo ASCT, while those who do not meet the criteria or refuse to undergo ASCT, will continue with 2 cycles of immunochemotherapy.
Study: NCT03213977
Drug: R-CEOP90
Normalized name: R
Approvals — FDA: no, EMA: no, PMDA: no
Description: R-CEOP90 treatment for DLBCL patients between 16 to 60 years with high risk. Patients who meet the criteria for ASCT after reaching CR or PR will undergo ASCT, while those who do not meet the criteria or refuse to undergo ASCT, will continue with 2 cycles of immunochemotherapy.
Study: NCT02705768
Drug: Oxcarbazepine
Normalized name: Oxcarbazepine
DrugBank: Oxcarbazepine (DB00776)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxcarbazepine will be started with 10mg/kg daily dose for one week followed by 15mg/kg daily for next one week and then will be increased to 20mg/kg for next two weeks.
Study: NCT02922192
Drug: TNF-α antagonists, non-TNFs, DMARD non-biologics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exposure to TNF- α antagonists, non-TNF- α antagonists, oral DMARD, or non-biologic agents.
Study: NCT00000450
Drug: Matched Placebo Tablet
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01668030
Drug: Enzymatic agent
Normalized name: hydrolyzed sericin (enzymatic; 2500 MW)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enzymatic agent
Study: NCT04266106
Drug: SuperBio probiotic
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: One capsule po BID for 28 days
Study: NCT01958879
Drug: ringer without corticosteroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mL Ringer solution
Study: NCT02067741
Drug: CR1447
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg, corresponding to two 4 g stick packs applications twice daily
Study: NCT00779311
Drug: mFOLFOX6 regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: The mFOLFOX6 regimen will be administered on Day 1 of each treatment cycle. This regimen consists of oxaliplatin 85 mg/m2 IV given over 2 hours, leucovorin 400 mg/m2 IV given over 2 hours, and fluorouracil 400 mg/m2 IV bolus, followed by fluorouracil 1200 mg/m2 per day for 2 days continuous infusion.
Study: NCT02855450
Drug: rhNGF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant Human Nerve Growth Factor 180μg/ml (one 35 μl drop equals to 6.30 μg of rhNGF) reconstituted solution three times a day (TID) for 8 weeks of treatment.
Study: NCT02855450
Drug: Vehicle
Normalized name: Drug vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ophthalmic Placebo solution of the same composition as the test product with the exception of rhNGF reconstituted solution times a day (TID) for 8 weeks of treatment.
Study: NCT02306239
Drug: Norepinephrine
Normalized name: Norepinephrine
DrugBank: Norepinephrine (DB00368)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00866515
Drug: Placebo + GW642444M
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to match D1-6 + GW642444M 25ug single dose on D5
Study: NCT02438215
Drug: IRX4204
Approvals — FDA: no, EMA: no, PMDA: no
Description: IRX4204 is a potent and highly selective orally available and brain penetrant RXR nuclear receptor agonist small compound administered as gel capsules.
Study: NCT02098057
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: A total of 24 patients with NCGS and 12 healthy controls will be recruited for this study. The 24 patients with NCGS will be randomized to receive one of two diets (GFD or GCD) in a 1:1 ratio~Assessment of current diet and amount of gluten consumed will be determined by the dietitian and by means of a questionnaire at baseline. Subjects will have a 2-week run in period, in which they will continue or initiate a gluten free diet plan prepared by the dietitians. After the run-in period, participants will be randomized to either a gluten containing diet (GCD) or placebo (GFD) for 4 weeks.
Study: NCT01645085
Drug: MCC-based 13% drug loaded tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50mg tablets, dosed as 2 tablets (100mg total)
Study: NCT01645085
Drug: MCC-based 13% drug loaded tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 tablets (150mg total)
Study: NCT02146248
Drug: DepoProvera
Approvals — FDA: no, EMA: no, PMDA: no
Description: injectable hormonal contraceptive
Study: NCT00671814
Drug: TR-701
Approvals — FDA: no, EMA: no, PMDA: no
Description: TR-701 will be given as single oral doses in Cohorts 1-5 and as once daily oral doses for 21 days in cohorts 6-8.
Study: NCT00671814
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be given once for cohorts 1-5, once daily for 21 days for cohorts 6-8, and twice daily for 21 days for cohort 10.
Study: NCT01315847
Drug: [11C]MK-4232
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single intravenous doses of \~300 MBq \[11C\]MK-4232 administered as a 5 minute infusion (Part I - Baseline, Period 1 and 2; Part III - Period 1 Baseline and Period 1, and Period 2 Baseline and Period 2)
Study: NCT04101760
Drug: Long-acting granulocyte colony stimulating factor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will accept long-acting granulocyte colony stimulating factor at 48 hour after the chemotherapy
Study: NCT03694041
Drug: SAD: APX-115
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: APX-115 SAD APX-115 SAD for 1day
Study: NCT03694041
Drug: SAD: Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: Placebo Placebo for 1day
Study: NCT03694041
Drug: MAD: APX-115
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: APX-115 MAD APX-115 MAD repeatedly administered.
Study: NCT03694041
Drug: MAD: Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching study drug will be repeatedly administered.
Study: NCT03571256
Drug: TEV-50717
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6-, 9-, 12-, 15-, and 18 mg oral tablets
Study: NCT03571256
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matched to TEV-50717 tablets will be taken BID.
Study: NCT00977015
Drug: Treatment A
Normalized name: Nix Ultra Lice Treatment And Prevention Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled, 750/150, single dose
Study: NCT00977015
Drug: Treatment B
Normalized name: PanOxyl Acne Treatment Bar
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled, 750/150, single dose
Study: NCT00764478
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo sublingual tablet, administered BID for 21 days
Study: NCT00575094
Drug: tigecycline
Normalized name: Tigecycline
DrugBank: Tigecycline (DB00560)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dosage form: Tigecycline 50 mg for injection (Lyophilized powder in 5 mL vial) Dosage frequency: Tigecycline 100 mg loading followed by 50 mg every 12 hrs (bid) Duration of therapy: 7 to 14 days
Study: NCT00245414
Drug: Pegasys®
Approvals — FDA: no, EMA: no, PMDA: no
Description: 180μg for s.c./week for 48 weeks
Study: NCT00245414
Drug: Pegasys®
Approvals — FDA: no, EMA: no, PMDA: no
Description: 180μg for s.c./week for 24 weeks
Study: NCT00466583
Drug: Intravenous EZN-2968 (anti-HIF-1α LNA AS-ODN)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV infusion of EZN 2968 given in 6 week cycles for (3 weeks on 3 weeks off) until recommended phase 2 dose identified. Up to 3 intensification cohorts will receive the recommended Phase 2 dose of EZN-2968.
Study: NCT03722914
Drug: blank control 0mg
Normalized name: acid black 52
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 mg/pellet, 1pellet/time, 3times/day
Study: NCT04545788
Drug: Total oral short-term therapy that includes linezolid, bedaquiline and/or cycloserine.
Approvals — FDA: no, EMA: no, PMDA: no
Description: AM is the traditional anti-TB drugs. Linezolid, bedaquiline and/or cycloserine, that might have potential efficacy of replacing injectable anti-TB drugs, are included into the total oral short-term therapy, and replace AM.
Study: NCT01112423
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsules, Oral, 0 mg, once daily, 28 days
Study: NCT01709981
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 1 to 2 hours prior PCI, followed by Placebo 1 hour later
Study: NCT01240408
Drug: HOPE
Normalized name: LIQUID HOPE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg lenvatinib (1x10 mg lenvatinib capsule) with food
Study: NCT01240408
Drug: HOPE
Normalized name: LIQUID HOPE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg lenvatinib (1x10 mg lenvatinib capsule) without food
Study: NCT01309438
Drug: Erythromycin (normal renal function)
Normalized name: Erythromycin
DrugBank: Erythromycin (DB00199)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: One 500 mg tablet taken orally (by mouth) three times daily on Days 1 to 6 of Treatment Period 2
Study: NCT01309438
Drug: Erythromycin (mild and moderate renal function)
Normalized name: Erythromycin
DrugBank: Erythromycin (DB00199)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: One 500 mg tablet taken orally (by mouth) three times daily on Days 1 to 6 of Treatment Periods 2 and 3
Study: NCT00001449
Drug: leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01763866
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered orally once a day
Study: NCT01763866
Drug: Simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered orally once a day
Study: NCT03971500
Drug: AntiPlatelet therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: AntiPlatelet therapy with ticagrelor + aspirin or ticagrelor alone.
Study: NCT02637726
Drug: Remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Remifentanil at discretion of the anesthesiologist
Study: NCT01352065
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet, 10 mg per day, single per day, 8 weeks
Study: NCT04275050
Drug: TQB3303
Approvals — FDA: no, EMA: no, PMDA: no
Description: TQB3303 tablet is a small molecule oral drug inhibiting cyclin-dependent kinases 4 and 6 (CDK4 / 6).
Study: NCT00141557
Drug: esterified estrogens 1.25mg and methyltestosterone 2.5mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: ESTRATEST® administered orally QD
Study: NCT03485092
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo tablets for oral self administration once a day
Study: NCT03143972
Drug: Remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single drug administration
Study: NCT00006372
Drug: pegylated liposomal doxorubicin hydrochloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients receive doxorubicin HCl liposome IV over 1-2.5 hours on day 1. Treatment continues every 28 days in the absence of disease progression or unacceptable toxicity.
Study: NCT02492087
Drug: Normal saline 0.9%
Normalized name: BD Posiflush Normal Saline 0.9% Prefilled Syringe Solution for Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sterile Normal saline 0.9% 120mls solution
Study: NCT02905058
Drug: Ketoprofen
Normalized name: Ketoprofen
DrugBank: Ketoprofen (DB01009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral non-steroidal antiinflammatory drug
Study: NCT02905058
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00017095
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00476996
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral or parenteral repeating dose
Study: NCT00476996
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous repeating dose
Study: NCT01148316
Drug: fluoxetine
Normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: drops or capsules, 10 to 80mg/Day for 14 weeks (first treatment) and as add-on to group CBT non-responders for additional 14 weeks
Study: NCT00017095
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00082043
Drug: Placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05049447
Drug: Pascoflair
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 x 2 tablets (single-dose)
Study: NCT00305747
Drug: BR-DIM
Normalized name: Respa-BR
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg orally (po) twice daily. May continue treatment for 12 months, however patients will be taken off study if their disease progresses, or have intolerable side effects.
Study: NCT02679196
Drug: KA2237
Approvals — FDA: no, EMA: no, PMDA: no
Description: PI3 Kinase p110β/δ inhibitor
Study: NCT02501837
Drug: Syntocinon-Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal administration of 24 IU Oxytocin
Study: NCT01711541
Drug: Fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00992732
Drug: HQK-1004
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1,000 mg/kg/day administered IV 24 hours/day for 5 days (Days 1-5 of each 21 day cycle)
Study: NCT02204813
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: A liquid mixed meal containing 1.5 grams of acetaminophen will be ingested in 7 equal portions from 0-30 minutes.~Starting at minus 15 minutes, an intravenous infusion of albumin alone (placebo) will be administered for 5.25 hours.
Study: NCT02204813
Drug: Lo-Xenin
Approvals — FDA: no, EMA: no, PMDA: no
Description: A liquid mixed meal containing 1.5 grams of acetaminophen will be ingested in 7 equal portions from 0-30 minutes.~Starting at minus 15 minutes, an intravenous infusion of xenin-25 at a dose of 4 pmoles/kg/min will be administered for 5.25 hours.
Study: NCT00225147
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: saline solution
Study: NCT01867645
Drug: IgM-enriched Intravenous Immunoglobulins
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: IgM-enriched IVIG (Pentaglobin, Biotest Pharma GmbH, Dreieich, Germany) at a dose of 0.25g/kg body weight/day as a continuous intravenous infusion at a rate of 2g/h over a period of 3 days.
Study: NCT03713216
Drug: Naldebain
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg Nalbuphine sebacate
Study: NCT00698035
Drug: Testosterone Cream
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1% micronized in velvachol - 0.5 gm of cream vaginally each night for two weeks, then 3 times a week for total of 12 weeks of treatment
Study: NCT00861588
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: starch placebo
Study: NCT02825147
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01287546
Drug: LY2875358
Approvals — FDA: no, EMA: no, PMDA: no
Description: Part A Dose escalation of LY2875358 administered intravenously (IV), Day 1 and 15 every 28 days for at least two cycles.
Study: NCT00209170
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: A sugar pill taken as one to two tablets daily for 6 months.
Study: NCT02317341
Drug: Placebo (saline)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given intravenously over 40 minutes
Study: NCT01959399
Drug: ASP015K
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral tablet
Study: NCT01959399
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: oral tablet
Study: NCT00442676
Drug: Celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Capsule, 200 mg/day until 32 weeks of gestation
Study: NCT00442676
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gelatin capsules of lactose
Study: NCT01933256
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00645918
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral, 6 pill loading dose on day of randomization; one pill daily for 6 months starting on day of randomization
Study: NCT02538367
Drug: YH12852 IR 0.05mg
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02538367
Drug: YH12852 IR 0.1mg
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02538367
Drug: YH12852 DR1 4mg
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02538367
Drug: YH12852 DR2 8mg
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04008901
Drug: BST-104 (Lonicera Flos Extract)
Normalized name: Lonicera japonica top extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: 175 mg of Lonicera Flos extract in 1 tablet (300 mg)
Study: NCT04008901
Drug: Placebo oral tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 mg of Lonicera Flos extract in 1 tablet (300 mg)
Study: NCT02029638
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1. Low dose pre-transplant cyclophosphamide will be administered intravenously (IV) over 1- 2 hours, (depending on volume) on Days -6 and -5. The dose of pre-transplant cyclophosphamide is 14.5 mg/kg/day.~2. High dose cyclophosphamide \[50mg/kg (Ideal Body Weight)\] will be administered on Day 3 post-transplant (within 60 to 72 hours of marrow infusion) and on Day 4 post-transplant. Cyclophosphamide will be given IV over 1-2 hours depending on volume.
Study: NCT02029638
Drug: acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 650 mg orally prior to antithymocyte globulin infusion.
Study: NCT00684112
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients in this arm of the study will receive two identical placebo capsules 1 hour before surgery.
Study: NCT04387526
Drug: (SOF and DCV)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04387526
Drug: (SOF, DCV, and RBV)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00249977
Drug: Capecitabine in Combination with Cisplatin and Irinotecan
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cisplatin 50 mg/m2 on day 1 (course 1) or day 11 (subsequent courses) Irinotecan 50 mg/m2 on day 1, 8, and 15 (course 1) or day 11, 18 and 25 (subsequent courses).~Capecitabine will be administered from day 1 to day 10 PO starting on course 2.
Study: NCT00237445
Drug: telithromycin
Normalized name: Telithromycin
DrugBank: Telithromycin (DB00976)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00237445
Drug: azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT04198233
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo suppository
Study: NCT04504435
Drug: GSK3494245
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule of 10-250 mg dose strength will be provided in labelled High Density Polyethylene (HDPE) bottles.
Study: NCT04504435
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo capsules will be provided
Study: NCT01965912
Drug: Kuvan®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kuvan® oral soluble tablet will be administered once daily along with Phenylalanine-restricted diet for a period of 7 years. Dosage of Kuvan® could range from 5 to 20 milligram per kilogram per day (mg/kg/day), as per Summary of Product Characteristics (SPC).
Study: NCT01224587
Drug: D1000078
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral, one single dose
Study: NCT01224587
Drug: D1000082
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral, one single dose
Study: NCT01224587
Drug: D1000083
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral, one single dose
Study: NCT01224587
Drug: D1000085
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral, one single dose
Study: NCT01442532
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Form=tablet, route=oral use, for 14 days
Study: NCT00729326
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: subcutaneous injection (5mcg or 10mcg), twice a day
Study: NCT00729326
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral administration (100mg), once a day in the morning